Resources Management Corp CT ADV Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Resources Management Corp CT ADV raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 7.9% in the second quarter, Holdings Channel.com reports. The fund owned 14,313 shares of the company’s stock after buying an additional 1,049 shares during the quarter. Resources Management Corp CT ADV’s holdings in Zoetis were worth $2,481,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Webster Bank N. A. boosted its position in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Zoetis in the fourth quarter worth about $40,000. LRI Investments LLC purchased a new stake in shares of Zoetis in the first quarter worth about $43,000. Hazlett Burt & Watson Inc. boosted its position in shares of Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after buying an additional 102 shares during the period. Finally, Central Valley Advisors LLC purchased a new stake in shares of Zoetis in the second quarter worth about $49,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $193.59 on Tuesday. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock has a fifty day moving average of $185.01 and a 200-day moving average of $174.42. The company has a market capitalization of $88.33 billion, a PE ratio of 37.30, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.41 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ZTS has been the subject of several analyst reports. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus boosted their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler boosted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, BTIG Research boosted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus target price of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.